JAGSONPAL PHARMACEUTICALS LTD.
BSE: 507789
values in crores
Revenue & Profit Trend
in croresRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|---|
| INCOME | ||||||||
| Revenue | 82.23+28.1% | 64.20-12.0% | 72.94-2.0% | 74.47-1.5% | 75.61+29.1% | 58.56-20.9% | 74.03-0.9% | 74.69 |
| Other Income | 2.83-10.6% | 3.17+6.5% | 2.98-1.7% | 3.03+7.2% | 2.83+2.0% | 2.77+19.3% | 2.32+40.4% | 1.65 |
| Total Income | 85.06+26.3% | 67.37-11.3% | 75.92-2.0% | 77.49-1.2% | 78.44+27.9% | 61.33-19.7% | 76.35+0.0% | 76.35 |
| EXPENSES | ||||||||
| Expenditure | 67.39+21.2% | 55.62-6.2% | 59.32-2.2% | 60.68-5.2% | 64.01+22.1% | 52.41-13.9% | 60.86-0.2% | 60.98 |
| Tax | 4.49+50.0% | 2.99-16.1% | 3.57-15.7% | 4.24+16.5% | 3.64+71.1% | 2.13-68.2% | 6.68+70.9% | 3.91 |
| PROFIT | ||||||||
| PBT | 17.68+50.4% | 11.76-19.0% | 14.52-13.6% | 16.81+16.5% | 14.43+65.7% | 8.71-77.5% | 38.67+151.6% | 15.37 |
| Net Profit | 13.19+50.5% | 8.76-20.0% | 10.95-12.9% | 12.57+16.5% | 10.79+64.0% | 6.58-79.4% | 31.99+179.2% | 11.46 |
| KEY METRICS | ||||||||
| OPM % | 20.97%+3.59pp | 17.38%-2.07pp | 19.45%-2.62pp | 22.07%+3.27pp | 18.80%+4.28pp | 14.52%-30.98pp | 45.50%+30.58pp | 14.92% |
| NPM % | 15.50%+2.49pp | 13.01%-1.41pp | 14.42%-1.81pp | 16.23%+2.47pp | 13.76%+3.03pp | 10.73%-31.17pp | 41.90%+26.89pp | 15.01% |
| EPS | 2.00+60.0% | 1.25-25.1% | 1.67-11.2% | 1.88+17.5% | 1.60+63.3% | 0.98-79.3% | 4.74+10.5% | 4.29 |
Corporate Events
Board MeetingJAGSNPHARM
202629Jul
Board Meeting
The meeting of the Board of Directors is scheduled to be hel…
BSE Filing ↗ Board MeetingJAGSNPHARM
202625Jun
Board Meeting
The Board of Directors considered and approved the appointme…
BSE Filing ↗ Board MeetingJAGSNPHARM
202625Jun
Board Meeting
The Board of Directors considered and approved the appointme…
BSE Filing ↗ Board MeetingJAGSNPHARM
202627Apr
Board Meeting
The Board of Directors recommended a dividend of Rs. 4/- pe…
BSE Filing ↗ Board MeetingJAGSNPHARM
202612Mar
Board Meeting
To consider and approve the proposal for Buyback of its full…
BSE Filing ↗ Board MeetingJAGSNPHARM
20269Mar
Board Meeting
Approval for the grant of employee stock options under Jagso…
BSE Filing ↗ Board MeetingJAGSNPHARM
202423Oct
Board Meeting
Unaudited Financial Results of the Company for the quarter a…
BSE Filing ↗ Board MeetingJAGSNPHARM
20242Feb
Board Meeting
Consider and approve Unaudited Financial Results of the Comp…
BSE Filing ↗ Board MeetingJAGSNPHARM
20233Nov
Board Meeting
Consider and approve the Unaudited Financial Results
BSE Filing ↗